Why the study?
Does the synthetic thrombin inhibitor MD-805 provide effective anticoagulation in patients after cardiovascular surgery and in patients with disseminated intravascular coagulation?
Does the synthetic thrombin inhibitor MD-805 provide effective anticoagulation in patients after cardiovascular surgery and in patients with disseminated intravascular coagulation?
MD-805 is an effective anticoagulant for patients after cardiovascular surgery and for treating DIC, particularly when antithrombin III levels are low.
MD-805 shows promise for post-CVS anticoagulation and DIC; leaves open efficacy and safety in prospective trials.
A synthetic thrombin inhibitor, MD-805, was used to anticoagulate 15 patients after cardiovascular surgery (CVS). A mean infusion rate of 0.71 +/- 0.1 (SD) microgram/kg . min maintained an activated coagulation time of about 150 sec in all patients, and significantly prolonged both activated partial thromboplastin time and prothrombin time. MD-805 was also administered to ten patients with disseminated intravascular coagulation (DIC), eight of whom had not responded to either heparin or gabexate mesilate (FOY), and eight of whom had circulating antithrombin III levels below 20 mg/dl. MD-805 therapy was successful in nine DIC patients. These results recommend MD-805 anticoagulant therapy after CVS and for treatment of DIC, especially when circulating levels of antithrombin III are low.
No takes yet. Share an insight, caveat, or question.
Kumon et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: